Evidence map›Paper›PMID 32162797›Full record

ArticleThe oncologist2020

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Hironori Fujii, Nobuhisa Matsuhashi, Mika Kitahora, Takao Takahashi, Chiemi Hirose, Hirotoshi Iihara, Yunami Yamada, Daichi Watanabe, Takuma Ishihara, Akio Suzuki and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 5 pooled it
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Observational
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Hironori Fujii *Department of Pharmacy, Gifu University Hospital, Gifu, Japan.ORCID 0000-0003-0944-7290
Nobuhisa Matsuhashi *Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Mika KitahoraDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Takao TakahashiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Chiemi HiroseDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Hirotoshi IiharaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Yunami YamadaDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Daichi WatanabeDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Takuma IshiharaInnovative and Clinical Research Promotion Center, Gifu University Hospital, Gifu, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, Gifu, Japan.
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan.
Gifu University Hospital · JPGifu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTAS-102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS-102 improves clinical outcomes in refractory mCRC. PATIENTS AND

methodsWe retrospectively analyzed data from Japanese patients with refractory mCRC who received TAS-102 (35 mg/m

resultsData from 57 patients were analyzed (T-B group: 21 patients, T group: 36 patients). Median OS was significantly longer in the T-B group than the T group (14.4 months vs. 4.5 months, p < .001). Cox proportional hazard analysis showed that combination therapy with Bmab was significantly correlated with OS. Propensity score matched analysis confirmed that the median OS was significantly longer in the T-B group than the T group (14.4 months vs. 6.1 months, p = .006) and that there was a significant correlation between Bmab and OS. The incidence of hypertension (grade ≥2) as an adverse event was significantly higher in the T-B group than the T group (23.8% vs. 0.0%, p = .005), whereas other adverse events were comparable between the two groups.

conclusionTreatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC refractory to standard therapies. IMPLICATIONS FOR PRACTICE: Combining bevacizumab (Bmab) with TAS-102 significantly improved overall survival and several prognostic indicators in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, with manageable toxicities. Treatment with Bmab in combination with TAS-102 is significantly associated with improved clinical outcomes in patients with mCRC.

Indexed as

Colorectal NeoplasmsThymineAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug CombinationsHumansPyrrolidinesRetrospective StudiesTrifluridineUracilBevacizumabDrug CombinationsPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationUracilBevacizumabColorectal neoplasmsDrug-related adverse reactionsSurvivalTrifluridine

Identifiers

PMID32162797
PMCPMC7066722
OpenAlexW2990121117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.